Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors
- PMID: 22275880
- PMCID: PMC3223722
- DOI: 10.3389/fnmol.2011.00047
Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors
Abstract
The constitutively active protein glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, acts paradoxically as a tumor suppressor in some cancers while potentiates growth in others. Deciphering what governs its actions is vital for understanding many pathological conditions, including brain cancer. What are seemingly disparate roles of GSK3 stems from the complex regulation of many cellular functions by GSK3. This review focuses on the regulation of GSK3, its role in survival, apoptosis and DNA damage, and finally its potential therapeutic impact in brain cancer. A thorough understanding of this versatile protein is critical for improving the outcome of various diseases, especially cancer.
Keywords: DNA damage; NFκB; apoptosis and autophagy; brain cancer; epidermal growth factor receptor; glycogen synthase kinase 3; lithium; neuroprotection.
Figures



Similar articles
-
Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.J Biol Chem. 2015 Feb 27;290(9):5592-605. doi: 10.1074/jbc.M114.616714. Epub 2015 Jan 5. J Biol Chem. 2015. PMID: 25561726 Free PMC article.
-
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.Neurochem Res. 2007 Apr-May;32(4-5):577-95. doi: 10.1007/s11064-006-9128-5. Epub 2006 Aug 30. Neurochem Res. 2007. PMID: 16944320 Free PMC article. Review.
-
Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax.Blood. 2001 Sep 1;98(5):1374-81. doi: 10.1182/blood.v98.5.1374. Blood. 2001. PMID: 11520785
-
Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.Pharmacol Ther. 2015 Apr;148:114-31. doi: 10.1016/j.pharmthera.2014.11.016. Epub 2014 Nov 27. Pharmacol Ther. 2015. PMID: 25435019 Free PMC article. Review.
-
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26. Biomed Pharmacother. 2020. PMID: 32470749
Cited by
-
Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.Pharmacol Rep. 2021 Feb;73(1):211-226. doi: 10.1007/s43440-020-00162-7. Epub 2020 Oct 8. Pharmacol Rep. 2021. PMID: 33030673
-
Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition.Front Oncol. 2022 Mar 24;12:824594. doi: 10.3389/fonc.2022.824594. eCollection 2022. Front Oncol. 2022. PMID: 35402240 Free PMC article.
-
The intersection between DNA damage response and cell death pathways.Exp Oncol. 2012 Oct;34(3):243-54. Exp Oncol. 2012. PMID: 23070009 Free PMC article. Review.
-
Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation.iScience. 2021 Jan 13;24(2):102058. doi: 10.1016/j.isci.2021.102058. eCollection 2021 Feb 19. iScience. 2021. PMID: 33554064 Free PMC article.
-
Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system.Pharmacol Rev. 2014 Jul;66(3):815-68. doi: 10.1124/pr.113.007757. Pharmacol Rev. 2014. PMID: 24958636 Free PMC article. Review.
References
-
- Adler J. T., Cook M., Luo Y., Pitt S. C., Ju J., Li W., Shen B., Kunnimalaiyaan M., Chen H. (2009). Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol. Cancer Ther. 8, 914–92010.1158/1535-7163.MCT-08-0712 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials